Cingulate (CING) Stock Price, News & Analysis

Company Overview

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Key Stats

• Today's Range: $3.90 to $4.07
• 50-Day Range: $3.68 to $5.73
• 52-Week Range: $3.02 to $9.69
• Volume: 79,602 shs
• Average Volume: 168,017 shs
• Market Capitalization: $21.59 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $26.25
• Consensus Rating: Buy

Cingulate Stock Analysis - MarketRank™

Cingulate scored higher than 47% of companies evaluated by MarketBeat, and ranked 618th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Cingulate has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cingulate has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cingulate are expected to grow in the coming year, from ($11.69) to ($4.95) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cingulate is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cingulate is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cingulate has a P/B Ratio of 3.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.54% of the float of Cingulate has been sold short.

Short Interest Ratio / Days to Cover

Cingulate has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cingulate has recently increased by 38.17%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cingulate does not currently pay a dividend.

Dividend Growth

Cingulate does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.54% of the float of Cingulate has been sold short.

Short Interest Ratio / Days to Cover

Cingulate has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cingulate has recently increased by 38.17%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: -0.07

News Sentiment

Cingulate has a news sentiment score of -0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.09 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Cingulate this week, compared to 2 articles on an average week.

Search Interest

7 people have searched for CING on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.

MarketBeat Follows

3 people have added Cingulate to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cingulate insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.04% of the stock of Cingulate is held by insiders.

Percentage Held by Institutions

41.31% of the stock of Cingulate is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CING Stock Analysis - Frequently Asked Questions

How have CING shares performed this year?

Cingulate's stock was trading at $4.93 on January 1st, 2025. Since then, CING stock has decreased by 19.1% and is now trading at $3.99.

How were Cingulate's earnings last quarter?

Cingulate Inc. (NASDAQ:CING) released its quarterly earnings results on Tuesday, August, 19th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by $0.27.

When did Cingulate's stock split?

Shares of Cingulate reverse split on Thursday, November 30th 2023.The 1-20 reverse split was announced on Thursday, November 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Cingulate IPO?

Cingulate (CING) raised $29 million in an initial public offering (IPO) on Wednesday, December 8th 2021. The company issued 4,166,666 shares at a price of $6.00-$8.00 per share.

Who are Cingulate's major shareholders?

Cingulate's top institutional investors include XTX Topco Ltd (0.21%) and Bank of America Corp DE (0.14%). Insiders that own company stock include Peter J Werth, Gregg Wm Givens, Jennifer L Callahan, Shane J Schaffer, Craig S Gilgallon and Laurie Myers.
View institutional ownership trends.

How do I buy shares of Cingulate?

Shares of CING stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cingulate own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cingulate investors own include NVIDIA (NVDA), Windtree Therapeutics (WINT), AMC Entertainment (AMC), Sonnet BioTherapeutics (SONN), ARMOUR Residential REIT (ARR), BioCardia (BCDA) and Altamira Therapeutics (CYTO).

Company Calendar

• Last Earnings: 8/19/2025
• Today: 8/31/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CING
• CIK: 1862150
• Web: www.cingulate.com
• Phone: 913-942-2300
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Cingulate: $26.25
• High Price Target: $62.00
• Low Price Target: $11.00
• Potential Upside/Downside: +557.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.55 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -232.16%
• Return on Assets: -132.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.52
• Quick Ratio: 1.52

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.02 per share
• Price / Book: 3.91

Miscellaneous

• Outstanding Shares: 5,410,000
• Free Float: 5,193,000
• Market Cap: $21.59 million
• Optionable: Not Optionable
• Beta: -0.74